Actemra de Roche wins first victory in COVID-19 study in France (OTCMKTS: RHHBY)


Results of a study opened at the Assistance Publique-Hôpitaux de Paris evaluating that of Roche (OTCQX: RHHBY -0.6%), Actemra drug arthritis (tocilizumab) in hospital patients with moderate to severe pneumonia with COVID-19 pneumonia has shown therapeutic benefit.

65 patients received tocilizumab + standard treatment (SOC) while 64 patients received SOC. The primary objective was achieved, demonstrating a significantly lower proportion of patients in the tocilizumab arm who died or required ventilation compared to the SOC arm.

The results will be submitted for publication.

Tocilizumab is an interleukin-6 (IL-6) receptor antagonist. IL-6 is a pro-inflammatory protein (cytokine).


Please enter your comment!
Please enter your name here